The Amphilix proprietary linker platform enables the design of drug-drug conjugates with excellent target product profiles. Using this technology, Amphilix has discovered and is developing a First-in-Class and fully differentiated radioligand therapy for cancer.

Products, services, technology

The First-in-Class radioligand differentiates from competition:

  • New target, expressed in cancer cells and in tumor-associated growing blood vessels
  • Selective small molecule ligand with long residence time on the target
  • The specially designed linker defines an excellent in vivo profile
Cooperation possibilities

Based on its proprietary linker platform Amphilix has the potential to collaborate with other companies working on drug-drug conjugates to create molecules with optimal target product profiles. Examples include radioligand therapies, PROTACs, etc.

Some insights
Location
Additional address info
  • Girenhaldenweg 6, 4126 Bettingen
Facts & figures
  • Type of organization
    Private company
  • Year of foundation
    2020
  • Number of employees in Switzerland
    1-9
Key business